Accrual barriers and detection of early toxicity signal in older, less-fit patients Wednesday, January 08, 2020 Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials. This trial deliberately accrued older patients using broad enrolment criteria with the aim of improving outcomes in this patient population. See the interview here: https://ecancer.org/en/video/8495-azacitidine-plus-nivolumab-in-older-adults-with-aml-or-mds
